These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27417383)

  • 1. Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration.
    Real JP; Luna JD
    Acta Ophthalmol; 2016 Dec; 94(8):e803. PubMed ID: 27417383
    [No Abstract]   [Full Text] [Related]  

  • 2. SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch?
    Moisseiev E; Katz G; Moisseiev J; Loewenstein A; Goldstein M; Lomnicky Y; Abend Y; Treister G; Goldenberg D; Levkovitch-Verbin H
    Retina; 2015 Jul; 35(7):1323-30. PubMed ID: 26102434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
    Rahimy E; Rayess N; Ho AC; Regillo CD
    Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcomes after 5 years pro re nata treatment of neovascular age-related macular degeneration with ranibizumab.
    Airody A; Venugopal D; Allgar V; Gale RP
    Acta Ophthalmol; 2015 Sep; 93(6):e511-2. PubMed ID: 25488611
    [No Abstract]   [Full Text] [Related]  

  • 5. Visual outcomes in relation to time to treatment in neovascular age-related macular degeneration.
    Rasmussen A; Brandi S; Fuchs J; Hansen LH; Lund-Andersen H; Sander B; Larsen M
    Acta Ophthalmol; 2015 Nov; 93(7):616-20. PubMed ID: 26073051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Achieving balance in the treatment and monitoring of neovascular age-related macular degeneration in the real world: lessons from the Netherlands cohort of the AURA study.
    van Asten F; de Jong-Hesse Y; van Lith-Verhoeven JJC; Verbraak FD; Vromans JGF; Lau NC; Altemark A; Hoyng CB
    Acta Ophthalmol; 2019 Mar; 97(2):e323-e324. PubMed ID: 30318723
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of outcomes after switching treatment from intravitreal bevacizumab to ranibizumab in neovascular age-related macular degeneration.
    Kent JS; Iordanous Y; Mao A; Powell AM; Kent SS; Sheidow TG
    Can J Ophthalmol; 2012 Apr; 47(2):159-64. PubMed ID: 22560422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
    Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
    Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of wet age-related macular degeneration by ranibizumab in "real life" in France: treatment behaviours and associated visual outcome.
    Souied EH; Cohen SY; de Pouvourville G; Dupeyron G; Latour E; Ponthieux A; Weber M
    Acta Ophthalmol; 2015 Mar; 93(2):e179-80. PubMed ID: 25377519
    [No Abstract]   [Full Text] [Related]  

  • 10. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee H; Ji B; Chung H; Kim HC
    Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX).
    Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD
    Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degeneration.
    Johnson D; Sharma S
    Curr Opin Ophthalmol; 2013 May; 24(3):205-12. PubMed ID: 23518613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of intravitreal ranibizumab in phakic and pseudophakic neovascular age-related macular degeneration patients with good baseline visual acuity.
    Ozkaya A; Alkin Z; Yazici AT; Demirok A
    Retina; 2014 May; 34(5):853-9. PubMed ID: 24141904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
    Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
    Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from intravitreal ranibizumab to bevacizumab for the treatment of neovascular age-related macular degeneration: clinical comparison.
    Pinheiro-Costa J; Freitas-da-Costa P; Falcão MS; Brandão EM; Falcão-Reis F; Carneiro AM
    Ophthalmologica; 2014; 232(3):149-55. PubMed ID: 25196907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
    Shin JY; Kwon KY; Byeon SH
    Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch to Aflibercept in the Treatment of Neovascular AMD: One-Year Results in Clinical Practice.
    Pinheiro-Costa J; Costa JM; Beato JN; Freitas-da-Costa P; Brandão E; Falcão MS; Falcão-Reis F; Carneiro ÂM
    Ophthalmologica; 2015; 233(3-4):155-61. PubMed ID: 25896317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials.
    Agarwal A; Aggarwal K; Gupta V
    Middle East Afr J Ophthalmol; 2016; 23(1):27-37. PubMed ID: 26957836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.